|
294 Companies |
|
490 Products |
|
490 Products |
|
198 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...145146147148149150151152153154155156157» |
- dilmapimod (SB-681323) / GSK
Enrollment change: SB-681323-Methotrexate Interaction Study (clinicaltrials.gov) - Jan 12, 2012
P1, N=18, Completed, Sponsor: GlaxoSmithKline
N=15 --> 18
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 12, 2012
P1, N=40, Completed, Sponsor: Novo Nordisk
N=15 --> 18 Active, not recruiting --> Completed
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Enrollment change: Strategies to Improve Islet Survival (clinicaltrials.gov) - Jan 11, 2012
P2, N=5, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=24 --> 5
- Xolair (omalizumab) / Roche, Novartis
Enrollment change: Efficacy and Safety of Omalizumab in Bullous Pemphigoid (clinicaltrials.gov) - Jan 10, 2012
P4, N=2, Completed, Sponsor: University of Iowa
N=24 --> 5 N=12 --> 2
- New P1 trial: MDRS for Prevention of Nocturnal Hypoglycemia (clinicaltrials.gov) - Jan 10, 2012
P1, N=38, Completed, Sponsor: Rabin Medical Center
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Trial completion: A Study in Rheumatoid Arthritis (clinicaltrials.gov) - Jan 10, 2012
P1, N=32, Completed, Sponsor: Eli Lilly and Company
N=12 --> 2 Active, not recruiting --> Completed
- Xolair (omalizumab) / Roche, Novartis
Trial completion: Efficacy and Safety of Omalizumab in Bullous Pemphigoid (clinicaltrials.gov) - Jan 10, 2012
P4, N=2, Completed, Sponsor: University of Iowa
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Enrollment change: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 9, 2012
P2, N=182, Completed, Sponsor: Sanofi
Recruiting --> Completed N=241 --> 182
- New P2 trial: Pacing Activity Self-management for Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 9, 2012
P2, N=50, Recruiting, Sponsor: Vrije Universiteit Brussel
- ||||| Orencia (abatacept) / BMS
Trial initiation date: Methotrexate-Inadequate Response Study (clinicaltrials.gov) - Jan 8, 2012
P3, N=62, Completed, Sponsor: Bristol-Myers Squibb
N=241 --> 182 Initiation date: Jan 2008 --> Nov 2009
- ||||| Orencia (abatacept) / BMS
Enrollment change: Methotrexate-Inadequate Response Study (clinicaltrials.gov) - Jan 8, 2012
P3, N=62, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2008 --> Nov 2009 N=2472 --> 62
- |||| fletikumab (NNC109-0012) / Novo Nordisk
Trial completion: Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jan 8, 2012
P2, N=67, Completed, Sponsor: Novo Nordisk
N=2472 --> 62 Active, not recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion: Methotrexate-Inadequate Response Study (clinicaltrials.gov) - Jan 8, 2012
P3, N=62, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date, Adverse events: Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis (clinicaltrials.gov) - Jan 4, 2012
P1/2, N=22, Completed, Sponsor: Royan Institute
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Dec 2011
- Trial completion: Effect of Healing on Rheumatoid Arthritis (clinicaltrials.gov) - Jan 4, 2012
P=N/A, N=90, Completed, Sponsor: Henning Bliddal
Initiation date: Jul 2011 --> Dec 2011 Active, not recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open, IO biomarker: Study of Tocilizumab to Treat Polymyalgia Rheumatica (clinicaltrials.gov) - Jan 3, 2012
P2a, N=10, Recruiting, Sponsor: Hospital for Special Surgery, New York
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Diamyd (rhGAD65/alum) / Diamyd Medical
Enrollment closed: DIAPREV-IT: Diabetes Prevention - Immune Tolerance (clinicaltrials.gov) - Jan 3, 2012
P2, N=50, Active, not recruiting, Sponsor: Lund University
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- |||| Trial completion: Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Dec 30, 2011
P2, N=61, Completed, Sponsor: Symphogen A/S
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- prednisone / Generic mfg.
Trial initiation date: EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) - Dec 28, 2011
P3, N=11, Terminated, Sponsor: Michael Benatar
Active, not recruiting --> Completed Initiation date: May 2011 --> Dec 2011
- ||||| Orencia (abatacept) / BMS
Enrollment change: BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis (clinicaltrials.gov) - Dec 28, 2011
P3, N=122, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: May 2011 --> Dec 2011 N=200 --> 122
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab (clinicaltrials.gov) - Dec 28, 2011
P2, N=61, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||||| Orencia (abatacept) / BMS
Trial completion: BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis (clinicaltrials.gov) - Dec 28, 2011
P3, N=122, Completed, Sponsor: Bristol-Myers Squibb
N=200 --> 122 Active, not recruiting --> Completed
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: INcEREBRO: Insulin Detemir Action in Cerebro (clinicaltrials.gov) - Dec 28, 2011
P=N/A, N=40, Completed, Sponsor: VU University Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Effects of Nurse-counselling in the Improvement of the type1 Diabetes Control in Adolescents (clinicaltrials.gov) - Dec 28, 2011
P=N/A, N=77, Completed, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed Recruiting --> Completed
- DiaPep277 / Evotec, Amgen
Trial initiation date: OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 (clinicaltrials.gov) - Dec 27, 2011
P3, N=11, Active, not recruiting, Sponsor: Rabin Medical Center
Recruiting --> Completed Initiation date: Oct 2011 --> Jan 2012
- New P1 trial: Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients With Type 1 Diabetes (clinicaltrials.gov) - Dec 27, 2011
P1, N=25, Not yet recruiting, Sponsor: Rabin Medical Center
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Dec 26, 2011
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
- ||| Avonex (recombinant IFN-?-1a) / Biogen
New P1 trial: Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers (clinicaltrials.gov) - Dec 26, 2011
P1, N=110, Completed, Sponsor: Biogen Idec
- ||||| BIIB023 / Biogen
New P2 trial: ATLAS: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (clinicaltrials.gov) - Dec 22, 2011
P2, N=300, Recruiting, Sponsor: Biogen Idec
- | Enrollment open: Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial (clinicaltrials.gov) - Dec 22, 2011
P4, N=50, Recruiting, Sponsor: Brigham and Women's Hospital
Initiation date: Oct 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- toreforant (JNJ-38518168) / J&J
Enrollment change: A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (clinicaltrials.gov) - Dec 22, 2011
P1, N=20, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting N=16 --> 20
- ||||| Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) - Dec 22, 2011
P4, N=158, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| New P4 trial: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Dec 22, 2011
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
- atorvastatin / Generic mfg.
New P4 trial: Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes (clinicaltrials.gov) - Dec 21, 2011
P4, N=20, Completed, Sponsor: Karolinska Institutet
- || Enrollment change: Changing Diabetes (clinicaltrials.gov) - Dec 21, 2011
P=N/A, N=8304, Completed, Sponsor: Novo Nordisk
N=16 --> 20 N=15000 --> 8304
- ||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P2 trial: BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes (clinicaltrials.gov) - Dec 21, 2011
P2, N=70, Completed, Sponsor: Bristol-Myers Squibb
- ||| Trial completion: Changing Diabetes (clinicaltrials.gov) - Dec 21, 2011
P=N/A, N=8304, Completed, Sponsor: Novo Nordisk
N=15000 --> 8304 Enrolling by invitation --> Completed
- |||||||||| New P3 trial: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 20, 2011
P3, N=161, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- atacicept (VT-001) / Vera Therap
Trial termination: EMR 700461_014: Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil (clinicaltrials.gov) - Dec 20, 2011
P1, N=1, Terminated, Sponsor: EMD Serono
Enrolling by invitation --> Completed Suspended --> Terminated; Please see Purpose Statement below
- atacicept (VT-001) / Vera Therap
Enrollment change: EMR 700461_014: Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil (clinicaltrials.gov) - Dec 20, 2011
P1, N=1, Terminated, Sponsor: EMD Serono
Suspended --> Terminated; Please see Purpose Statement below N=25 --> 1
- Betaseron (IFN-?-1b) / Bayer
Enrollment change: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Dec 20, 2011
P=N/A, N=50, Active, not recruiting, Sponsor: Bayer
N=25 --> 1 N=100 --> 50
- | Benlysta (belimumab) / GSK
New P1 trial, IO biomarker: Japanese phase1 Study of Belimumab (IV vs SC) (clinicaltrials.gov) - Dec 20, 2011
P1, N=16, Completed, Sponsor: GlaxoSmithKline
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical data, Trial completion, Compliance: EviraEAST: EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=809, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=100 --> 50 Active, not recruiting --> Completed
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P1 trial: Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Dec 19, 2011
P1, N=32, Completed, Sponsor: Novo Nordisk
- ||||||| Humalog pen (insulin lispro) / Eli Lilly
Trial completion: Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use (clinicaltrials.gov) - Dec 18, 2011
P3, N=133, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Etanercept for the Treatment of Lupus Nephritis (clinicaltrials.gov) - Dec 15, 2011
P2, N=1, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=28 --> 1
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 14, 2011
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
N=28 --> 1 Initiation date: Sep 2011 --> Dec 2011
- ||||| New P4 trial: BONARTH: Benefit of Orthopedic Navigation in the ARThroplasty of the Hip (clinicaltrials.gov) - Dec 14, 2011
P4, N=89, Active, not recruiting, Sponsor: Aesculap AG
- Nerventra (laquinimod) / Active Biotech, Rebif (human IFN-?-1a) / EMD Serono
Trial initiation date: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability (clinicaltrials.gov) - Dec 14, 2011
P2, N=0, Withdrawn, Sponsor: Teva Pharmaceutical Industries
Initiation date: Sep 2011 --> Dec 2011 Initiation date: Jul 2011 --> Mar 2012
- | JNJ-39758979 / J&J
Trial completion: A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants (clinicaltrials.gov) - Dec 14, 2011
P1, N=21, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Initiation date: Jul 2011 --> Mar 2012 Active, not recruiting --> Completed